Scheme

Nippon India Nifty Pharma ETF

Holds 20 companies worth ₹1,736 Cr in Sept 2026.

Fund house
NipponThe fund house that runs this scheme.
AUM
₹1,736 CrNippon India Nifty Pharma ETF's AUM at the end of 30 Sept 2026, as AMFI reports it. Down 1.4% on Aug 2026, ₹1,761 Cr.
Largest holding
Sun Pharmaceutical Ind LtdSun Pharmaceutical Ind Ltd is 19.5% of this scheme's NAV.
Fund manager
Jitendra TolaniRuns it since 1 Feb 2025, as the fund house dates it.

Holdings^{(Jul 2021 – Sept 2026)}

Holdings in Sept 2026. Tick up to 2 to plot them.
Plot	20 companies ·	₹ Cr
	Sun Pharmaceutical Ind Ltd	339
	Divi s Laboratories Limited	208
	Laurus Labs Limited	136
	Cipla	133
	Dr Reddy s Laboratories Limited	132
	Torrent Pharmaceuticals Limited	124
	Lupin	86.8
	Aurobindo Pharma	81.4
	Glenmark Pharmaceuticals	61.9
	Alkem Laboratories Limited	54.8
	Cadila Healthcare	50.7
	Mankind Pharma Limited	50
	IPCA Laboratories Limited	47.1
	Biocon	45.4
	Gland Pharma Limited	40.7
	Sai Life Sciences Limited	37.1
	Wockhardt	30.8
	Ajanta Pharmaceuticals Limited	29.1
	Abbott India Limited	24.9
	Piramal Pharma Limited	22.6

Fig. 1.Market value of each ticked company in Nippon India Nifty Pharma ETF, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Fig. 2.This scheme's holdings, by market cap, by sector and by company. Hover a slice or a row; click a slice to open it.

Fig. 3.Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures. Click a column's header to sort by it.

Sun Pharmaceutical Ind Ltd	Equity	Pharmaceuticals & Biotechnology	18.6L	339	19.50
Divi s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	2.24L	208	11.97
Laurus Labs Limited	Equity	Pharmaceuticals & Biotechnology	6.86L	136	7.82
Cipla	Equity	Pharmaceuticals & Biotechnology	9.91L	133	7.68
Dr Reddy s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	10.7L	132	7.62
Torrent Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	2.59L	124	7.16
Lupin	Equity	Pharmaceuticals & Biotechnology	4.28L	86.8	5.00
Aurobindo Pharma	Equity	Pharmaceuticals & Biotechnology	4.87L	81.4	4.69
Glenmark Pharmaceuticals	Equity	Pharmaceuticals & Biotechnology	2.65L	61.9	3.56
Alkem Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	1.06L	54.8	3.16
Cadila Healthcare	Equity	Pharmaceuticals & Biotechnology	4.36L	50.7	2.92
Mankind Pharma Limited	Equity	Pharmaceuticals & Biotechnology	2L	50	2.88
IPCA Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	2.45L	47.1	2.71
Biocon	Equity	Pharmaceuticals & Biotechnology	12.3L	45.4	2.62
Gland Pharma Limited	Equity	Pharmaceuticals & Biotechnology	1.4L	40.7	2.34
Sai Life Sciences Limited	Equity	Pharmaceuticals & Biotechnology	2.44L	37.1	2.14
Wockhardt	Equity	Pharmaceuticals & Biotechnology	1.45L	30.8	1.77
Ajanta Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	80.3K	29.1	1.67
Abbott India Limited	Equity	Pharmaceuticals & Biotechnology	9.18K	24.9	1.43
Piramal Pharma Limited	Equity	Pharmaceuticals & Biotechnology	10.9L	22.6	1.30

Fig. 4.Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures.